CT-388Roche (Genentech)

What is CT-388?Overview

CT-388 is an investigational signal-biased dual GLP-1/GIP receptor agonist developed by Roche (via Genentech) after acquiring Carmot Therapeutics for $2.7 billion in January 2024. In Phase 1b trials, CT-388 demonstrated 18.8% placebo-adjusted weight loss at 24 weeks—one of the highest efficacy signals observed for any obesity medication at this stage—with 85% of patients achieving at least 10% weight loss.^[1]

What makes CT-388 particularly noteworthy is its "signal-biased" pharmacology: the drug was designed to activate GLP-1 and GIP receptors while minimizing β-arrestin recruitment, which theoretically leads to reduced receptor desensitization and prolonged pharmacological activity compared to standard dual agonists like tirzepatide (Zepbound).

• What It Is: Once-weekly subcutaneous injectable signal-biased GLP-1/GIP dual receptor agonist. Acquired by Roche from Carmot Therapeutics ($2.7B). Currently in Phase 2 trials with Phase 3 planned for H1 2026.
• Efficacy Data: Phase 1b: 18.8% placebo-adjusted weight loss at 24 weeks. 100% achieved ≥5%, 85% achieved ≥10%, 45% achieved ≥20%. In T2D patients: 3.0% HbA1c reduction at 12 weeks.^[1][4]
• Development Status: Phase 2 trials ongoing in obesity (NCT06525935) and T2D (NCT06628362). Phase 3 initiation H1 2026. Roche targeting 2030 market entry with >$3B peak sales projection.^[3]

Why CT-388 Matters: Roche has stated its ambition to become a "top 3" player in the obesity market. With CT-388's impressive Phase 1b data and Roche's massive commercial infrastructure, CT-388 represents a serious challenge to Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). Roche is also developing combination therapies (CT-388 + Petrelintide) that could address the nausea issues that limit tolerability of current GLP-1 medications.

For patients seeking alternatives to tirzepatide (Zepbound) or semaglutide (Wegovy), CT-388 represents a pipeline option that could offer potentially superior efficacy through its signal-biased mechanism—though it won't be available until 2030 at the earliest.

How CT-388 WorksSignal-Biased Dual-Agonist Mechanism

CT-388 works by simultaneously activating two key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). What sets CT-388 apart is its "signal-biased" design that preferentially activates cAMP signaling while minimizing β-arrestin recruitment at both receptors.^[2]

Why β-Arrestin Matters

When GLP-1 or GIP receptors are activated, they typically trigger two downstream pathways:

• cAMP Pathway: The "beneficial" pathway responsible for appetite suppression, insulin secretion, and metabolic effects that lead to weight loss and glucose control.
• β-Arrestin Pathway: Triggers receptor internalization and desensitization—essentially making the receptors "tired" and less responsive over time. This may limit drug efficacy with repeated dosing.
• CT-388's Advantage: By minimizing β-arrestin recruitment, CT-388 theoretically maintains receptor sensitivity and prolongs pharmacological activity, potentially leading to sustained efficacy.

Dual GLP-1/GIP Receptor Activation

Like tirzepatide (Zepbound/Mounjaro), CT-388 activates both GLP-1 and GIP receptors:

• GLP-1 Effects: Appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion.
• GIP Effects: Enhanced insulin response, potential adipose tissue effects, synergy with GLP-1 for greater weight loss.
• Balanced vs. Imbalanced: CT-388 is a "balanced" dual agonist at both receptors; tirzepatide is "imbalanced" favoring GIP over GLP-1.

Clinical EvidenceTrial Results

CT-388's development has progressed through Phase 1 with consistently positive results, leading to ongoing Phase 2 trials and planned Phase 3 initiation in H1 2026.

Phase 1 Dose-Finding Studies (2022-2023)

Design: Single-ascending dose (SAD: 0.5-7.5 mg) and multiple-ascending dose (MAD: 5-12 mg weekly for 4 weeks) studies in healthy obese volunteers.^[2]

• 4-Week MAD Results: Up to 8% weight loss with dose-dependent response
• Half-Life: ~6 days (135-151 hours) confirmed (supports weekly dosing)
• Safety: Well-tolerated with expected GI side effects

Phase 1b Trial (24 Weeks, Obesity Without T2D) — NCT04838405

Design: Randomized, double-blind, placebo-controlled trial in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Cohorts at 8 mg and 22 mg doses.^[1]

Results (Week 24, 22 mg dose):

• Placebo-adjusted weight loss: -18.8% (p < 0.001)
• ≥5% Weight Loss: 100% of patients
• ≥10% Weight Loss: 85% of patients
• ≥15% Weight Loss: 70% of patients
• ≥20% Weight Loss: 45% of patients
• Glycemic Effect: All pre-diabetic participants became normoglycemic

Phase 1 T2D Cohort (12 Weeks) — NCT04838405

Design: 12-week cohort in 19 adults with obesity and type 2 diabetes (14 CT-388, 5 placebo). Dose: 22 mg weekly.^[4]

Results (Week 12):

• HbA1c Reduction: 3.0% (CT-388) vs. 0.2% (placebo) — placebo-adj: 2.8%
• HbA1c ≤6.5%: 100% of CT-388 patients achieved this threshold
• HbA1c <5.7%: 50% of CT-388 patients (diabetes remission threshold)
• Weight Loss: 8.6% (CT-388) vs. 1.2% (placebo) — placebo-adj: 7.4%
• Discontinuations: 0 due to adverse events

Safety and Side EffectsSafety Profile

CT-388's safety profile in Phase 1 trials was consistent with the GLP-1/GIP agonist class, featuring predominantly gastrointestinal adverse events. Notably, the side effect rates were higher than some competitors, though the majority were mild-to-moderate and GI AEs decreased during the maintenance period.^[6]

Common Side Effects (Phase 1b, 22 mg dose)

• Nausea: 83.3% during titration → 54.2% in maintenance (mostly mild)
• Vomiting: 75.0% during titration → 33.3% in maintenance (mostly mild)
• Diarrhea: 54.2% during titration → 50.0% in maintenance
• Constipation: 58.3% during titration → 50.0% in maintenance
• Severity: Most TEAEs mild-to-moderate; no severe (Grade 3) in maintenance

Tolerability Indicators

• 22 mg Cohort Discontinuation: ~17% (4/24 patients)
• 8 mg Cohort Discontinuation: 1 patient
• T2D Cohort (12 weeks): 0 discontinuations due to AEs
• Serious Adverse Events: Not reported as a significant concern

Path to FDA ApprovalApproval Timeline

Current Status: Phase 2 trials ongoing. Roche announced Phase 3 initiation for H1 2026 at Pharma Day in September 2025. The company is targeting market entry by 2030.

Current AccessClinical Trials

CT-388 is not yet FDA-approved and is only accessible through clinical trial participation. Phase 2 trials are currently enrolling:

Note: Unlike Viking Therapeutics, Roche has substantial clinical trial infrastructure with sites globally. Check trial listings for locations near you.

Insurance Coverage OutlookCoverage Outlook

CT-388 is not yet FDA-approved and therefore not covered by any insurance plans. Post-approval coverage will depend on FDA labeling, pricing strategy, and payer negotiations.

Key Coverage Considerations

• Roche's Advantage: Unlike small biotechs, Roche has extensive payer relationships and commercial infrastructure that could facilitate better coverage negotiations.
• Competitive Landscape: CT-388 will enter a market with established competitors (Zepbound, Wegovy, potentially CagriSema, retatrutide). Payers may require step therapy through existing drugs first.
• Potential Differentiation: If signal-biased mechanism shows clinical advantages (better tolerability, sustained efficacy), this could support preferred formulary placement.
• Type 2 Diabetes Indication: If approved for T2D (Phase 2 ongoing), Medicare Part D coverage becomes possible.

Realistic Outlook: Roche's commercial strength is a significant advantage compared to smaller competitors. However, as a late market entrant, CT-388 will face an established competitive landscape. Patient assistance programs will be available.